Background: The ubiquitin-proteasome system is the primary proteolysis machine for controlling protein stability of the majority of regulatory proteins including those that are critical for cancer development. The forkhead box transcription factor FOXO3 plays a key role in regulating tumor suppression; however, the control of FOXO3 protein stability remains to be established. It is crucial to elucidate the molecular mechanisms underlying the ubiquitin-mediated degradation of FOXO3 tumor suppressor.
Introduction
FOXO3 (or FOXO3a) is a member of the forkhead box class O (FOXO) transcription factors which have been shown to play critical roles in modulating a number of cellular processes, such as metabolism, differentiation, and transformation in animal cells [1] [2] [3] [4] [5] [6] [7] . Strikingly, recent gene knockouts reveal FOXOs' vital functions in tumor suppression [8, 9] and the maintenance of the hematopoietic stem cell pool [8, 10, 11] . Activation of FOXO factors was shown to regulate the expression of specific target genes that modulate the cell metabolic state, oxidative stress, aging [1, 2, 12] , and those that control cell cycle progression including cyclin B and Polo-like kinase [13, 14] and DNA damage [15] [16] [17] .
While multiple mechanisms have been shown to regulate FOXO3 activity, there is a consensus that nuclear translocation of FOXO3 protein is critical to its regulation and function. Upon stimulation with growth factors, tyrosine kinase receptors trigger phosphoinositide 3-kinase (PI3K) to activate serine/threonine kinases such as the Akt family of protein kinases that phosphorylate FOXO3 protein. Phosphorylated FOXO3 protein then binds to 14-3-3 proteins that facilitate the translocation of FOXO3 from the nucleus into the cytoplasm [1, 2, 18] . This nuclear exclusion and translocation of FOXO3 into the cytoplasm inhibits FOXO3-dependent transcription. In the absence of stimulation from survival signals, Akt is inactivated in quiescent cells, which results in retention of FOXO3 protein in the nucleus and activation of FOXO3-dependent transcription. Other kinases such as IkB kinase (IKK)-b and JNK are also important in regulating nuclear exclusion of FOXO3, resulting in inhibition of FOXO3 function. Loss of function of FOXO3 through phosphorylation has been linked to tumorigenesis and poor patient survival in cancer, suggesting that FOXO3 is a key tumor suppressor [3, 5, 8, 19] .
In addition to phosphorylation, the protein degradation mechanism plays a key role in regulating FOXO3 tumor suppressor function. The ubiquitin (Ub)-proteasome pathway is critical for regulating degradation of several tumor suppressors such as p53, retinoblastoma, and p27Kip1 proteins in cancer cells and the E3 Ub-ligases important for the Ub-mediated degradation of these proteins have been studied [20, 21] . Interestingly, the FOXO3 protein stability is also regulated by the Ub-proteasome pathway [5, 6, 19] . However, the E3 Ub-ligases necessary for the Ub-mediated degradation of FOXO3 and their mechanisms are not well established. Thus, it is crucial to uncover the E3 Ub ligases required for FOXO3 protein degradation and elucidate their molecular mechanisms. Beta-transducin repeat-containing protein (bTrCP), a novel WD protein [22] [23] [24] [25] [26] , is a unique E3 Ubligase that plays a major role in substrate recognition in certain Ub-proteasome pathways [26] . It has been shown that bTrCP1 (also called Fbw1a or FWD1, etc.) ubiquitinates substrates such as phosphorylated IkB [23] and b-catenin [25] and regulates various signaling pathways, which are important for tumorigenesis [26] .
Here we show that bTrCP1 is a key E3 Ub-ligase that regulates the protein degradation of FOXO3 tumor suppressor. bTrCP1 interacts with FOXO3 and induces its Ub-dependent degradation in an IKKb-phosphorylation dependent manner. Using animal models, we further show that downregulation of FOXO3 protein level by ectopic expression of bTrCP1 in breast cancer cells promotes tumor proliferation or tumorigenesis. In contrast, upregulation of FOXO3 protein level by knocking down the expression of bTrCP1 in breast cancer cells suppresses their tumor growth in vivo. These results suggest that bTrCP1 may inhibit FOXO3 activity through a novel Ub-mediated degradation mechanism. The important biological and pathological significance of this mechanism in the development of cancer is discussed.
Results and Discussion
While we examined the expression of FOXO3 protein in various cancer cell lines, we unexpectedly found that the level of FOXO3 protein appeared to be inversely correlated with the level of bTrCP1 protein in various cancer cell lines (not shown), suggesting that bTrCP1 E3 Ub-ligase may contribute to a decrease of FOXO3. Consistently, over-expression of bTrCP1 reduced FOXO3 protein in 293T cells and this reduction could be reverted by treating cells with proteasome inhibitors such as MG-132 or clastro-lactacystin ( Figure S1A ), suggesting that bTrCP1 may decrease FOXO3 protein level through proteasomal degradation. Additionally, over-expression of mutant bTrCP1DF-myc, which contains a deletion at the N-terminal F-box domain (a.a. 17-52) that abolishes its E3 ligase activity [26] , increased the protein level of FOXO3 as compared to that in cells cotransfected with the FOXO3-Flag and bTrCP1-myc in the absence of proteasome inhibitor MG-132 ( Figure S1B ), suggesting that the expression of bTrCP1DF may inhibit the degradation of FOXO3 protein mediated by endogenous bTrCP1.
To determine if bTrCP1 interacts with endogenous FOXO3 in vivo, we carried out co-immunoprecipitation (IP) with an antibody (Ab) against FOXO3 followed by immunoblotting (IB) analysis with an Ab against bTrCP1 or a reciprocal co-IP with an Ab against bTrCP1 followed by IB analysis with an anti-FOXO3 Ab. Indeed, endogenous FOXO3 protein was associated with bTrCP1 protein in vivo ( Figure 1A ). Using the co-transfection approach, we further confirmed that HA-FOXO3 protein was specifically associated with myc-bTrCP1 protein in the transfected cells ( Figure S2A,B) .
Because the FOXO3 protein is targeted for proteasomal degradation after its phosphorylation in mammalian cells [5, 6, 19] , we sought to determine whether phosphorylation of FOXO3 by IKKb affects the protein level and ubiquitination (Ub) status of FOXO3. Indeed, Ub of FOXO3 protein was enhanced significantly when FOXO3a-myc was co-transfected with HA-Ub and IKKb in 293T cells in the absence of the IKKb inhibitor ( Figure 1B ). Ub of FOXO3 was abrogated by a point mutation at Ser-644 (FOXO3-S644A-myc, whose Ser residue at 644 was mutated to Ala and resistant to IKKb phosphorylation), suggesting that Ub of FOXO3 requires phosphorylation of FOXO3 at Ser-644 by IKKb. To demonstrate the requirement for IKKb activity in the Ub of FOXO3, we did experiments with the IKKb inhibitor and showed that inhibition of IKKb activity abrogated the Ub of FOXO3 in 293T cells ( Figure 1B) , suggesting that the Ub of FOXO3 is dependent on IKKb activity. As controls, we showed the endogenous bTrCP1 expression in 293T cells by IB analysis (Figure 1B) , suggesting that endogenous bTrCP1 is sufficient to facilitate IKKbmdeiated the Ub of FOXO3 in 293T cells. In addition, we showed that the IKKb inhibitor significantly repressed IKKb activity in phosphorylation of its cellular substrate IkB and overrode the IKKbmediated FOXO3 degradation in the treated cells ( Figure S3A-C) . To confirm if over-expression of IKKb induces FOXO3 protein degradation, we showed that co-transfection of FOXO3 with IKKb into 293T cells resulted in reduction of the protein level of FOXO3 and this reducing effect could be overridden by treating cells with various proteasome inhibitors ( Figure S2C ), suggesting that IKKb mediates proteasomal degradation of FOXO3 protein.
To determine whether bTrCP1 regulates the Ub status of FOXO3, we showed that Ub of FOXO3 was enhanced significantly when FOXO3-myc was co-transfected with HA-Ub plus bTrCP1 in 293T cells ( Figure 1C ), suggesting that bTrCP1 promotes Ub of FOXO3 in vivo. As controls, we showed the endogenous IKKb expression in 293T cells by IB analysis ( Figure 1C ), suggesting that endogenous IKKb is sufficient to facilitate the bTrCP1-induced Ub of FOXO3 in 293T cells. To demonstrate the requirement for bTrCP1 protein in the Ub of FOXO3, we did experiments with and without silencing of bTrCP1 by using bTrCP1-shRNA in the cotransfected 293T cells and showed that knockdown of bTrCP1 significantly attenuated the Ub of FOXO3 in these cells ( Figure 1D ), suggesting that the Ub of FOXO3 is dependent of bTrCP1 protein.
To titrate in transfected bTrCP1 and IKKb to determine whether there are synergistic effects of these proteins on FOXO3 Ub, we showed that increasing in transfected bTrCP1 indeed enhanced the Ub of FOXO3 proportionally in cells cotransfected both bTrCP1 and IKKb ( Figure 1E ). Similarly, we demonstrated that increasing in transfected IKKb augmented the Ub of FOXO3 correspondingly in cells cotransfected both IKKb and bTrCP1 ( Figure 1F ). These results imply that there may be an additive or synergistic effect of both proteins (IKKb and bTrCP1) on FOXO3 Ub. However, we do not have definitive evidence to prove that the observed increase of FOXO3 Ub is due to synergistic effects of these proteins on FOXO3 Ub.
To show direct Ub of FOXO3 by bTrCP1 E3 Ub-ligase, we performed the in vitro Ub reactions and showed that bTrCP1 induced Ub of FOXO3 protein in vitro ( Figure 1G ). Although overexpression of the mutant bTrCP1DF did not alter its binding to FOXO3 significantly ( Figure S2A ,B), Ub and degradation of FOXO3 protein were abrogated in the reactions using bTrCP1DF defective in E3 activity ( Figure 1H ; Figure S1B ), suggesting that Ub-mediated degradation of FOXO3 protein is directly consequential to the E3 activity of bTrCP1.
To confirm that the Ub-mediated FOXO3 protein degradation is mediated through bTrCP1, we compared the stability of FOXO3 protein in cells co-transfected with bTrCP1. Overexpression of bTrCP1 resulted in a rapid decrease in FOXO3 protein level (Figure 2A ; Figure S4A ), suggesting that bTrCP1 plays a crucial role in the degradation of FOXO3. We estimated that the half-life of FOXO3 is around 4 hours in cells overexpressing bTrCP1. In addition, silencing bTrCP1 in MCF-7 cells markedly increased FOXO3 protein ( Figure 2B ). Furthermore, mouse embryonic fibroblasts (MEF) lacking bTrCP1 also augmented the expression of FOXO3 protein ( Figure 2C,D) , suggesting that bTrCP1 may be essential for the Ub-mediated degradation of FOXO3.
As controls, we showed that MCF-7 and MEF cells express similar levels of IKKb protein ( Figure S4B-D) . It should be noted DMSO (control) or the IKKb inhibitor (2 mM) plus the proteasome inhibitor MG-132 (10 mM) for 5 hours. Total lysates were prepared and sonicated extensively for preventing non-covalent protein-protein associations, and subjected to IP with an anti-myc Ab and followed by IB analysis with an anti-HA Ab. The typical pattern of HA-tagged Ub was highlighted. The input IB data were performed with Abs against FOXO3, IKKb, phospho-IkBa (p-IkBa), IkBa, bTrCP1, and b-actin to show the expressions of transfected vectors in cells as indicated, the effect of the IKKb inhibitor (as indicated by the repression of p-IkBa level), and the integrity of each protein in total lysates used for IP. (C) IP was performed with the lysates of 293T cells that were cotransfected with the expression vectors as indicated, treated with MG-132 as described above, and followed by IB with an anti-HA Ab. The input IB data were performed with Abs against myc-tag, FOXO3, bTrCP1, IKKb, and b-actin to show the expressions of transfected vectors in cells and the integrity of lysates used for IP. (D) Firstly, 293T cells were transfected with either control-shRNA or bTrCP1-shRNA vectors. Twenty four hours post transfection, these cells were cotransfected with the expression vectors as indicated. Then, at 24 hours after cotransfection, cells were treated with MG-132 (20 mM) for 4 hours. The total lysates of these 293T cells were prepared and IP was performed as described above and followed by IB with an anti-HA Ab. The input IB data were performed with Abs against myc-tag, bTrCP1, IKKb, and b-actin as described. (E) 293T cells were cotransfected with various doses of bTrCP1 expression vector and mutant bTrCP1DF vector and other expression vectors as indicated. IP was performed with the lysates of these transfected 293T cells, treated with MG-132 as described above, and followed by IB with an anti-HA Ab. The input IB data were performed with Abs against FOXO3, IKKb, bTrCP1, and b-actin to show the expressions of transfected vectors and endogenous proteins in transfected cells and the integrity of lysates used for IP. (F) 293T cells were cotransfected with various doses of IKKb expression vector and other expression vectors as indicated. IP was performed with the lysates of these transfected 293T cells, treated with MG-132, and followed by IB with an anti-HA Ab as described above. The input IB data were performed with the indicated Abs as described above. (G) In vitro ubiquitination assays. The indicated target proteins GST-FO(1-300), GST-FO(301-673), and GST (negative control) were incubated with or without E3-ligase protein GST-bTrCP1 in Ub buffer containing E1, E2 (UbcH5b), Mg-ATP, biotinylated ubiquitin, and IKKb and analyzed by SDS-PAGE and IB with streptavidin conjugated with HRP or an anti-GST Ab as protein controls (lower panel). (H) The indicated target proteins were incubated with wild-type E3-ligase protein GST-bTrCP1 or mutant GST-bTrCP1DF in Ub buffer, and analyzed as described above. The positive signals are highlighted with *. doi:10.1371/journal.pone.0011171.g001 that FOXO3 does not seem to be degraded by endogenous bTrCP1 rapidly in 293T cells under normal conditions. Because the activity of IKKb is usually regulated by certain inflammatory cytokines such as tumor necrosis factor-a or other oncogenic factors, it is possible that FOXO3 is not subjected to fast degradation in the absence of overexpressed bTrCP1 due to the absence of constitutive phosphorylation of FOXO3 by IKKb under normal conditions.
Next, we sought to determine whether the bTrCP1-promoted, IKKb-dependent, degradation of FOXO3 affects its transactivational activity. Using the reporter co-transfection assays, we showed that ectopic expression of bTrCP1 resulted in a significant (,40%) decrease in FOXO3 transactivational activity ( Figure 2E ). The mutation of FOXO3 at Ser-644 abrogated the inhibitory effect of IKKb on the activity of FOXO3 while expression of Akt-DD resulted in a marked decrease in the activity of FOXO3-S644A ( Figure 2F ). In contrast to the wild-type (wt) FOXO3, overexpression of bTrCP1 could not facilitate the IKKb-mediated inhibition of mutant FOXO3-S644A.
To elucidate the biochemical mechanism underlying the bTrCP1-mediated degradation of FOXO3, we examined the binding between FOXO3 and bTrCP1 by using GST pull-down assays. We found that bTrCP1 bound FOXO3 mainly at the Cterminal portion [amino acid (a.a.) 301-673] ( Figure 3A ). Further mapping showed that bTrCP1 bound FOXO3 primarily at the Cterminal domain (a.a. 626-673) and, to a lesser extent, at an adjacent domain (a.a. 579-625) and a distant domain (a.a. 301-346) of FOXO3 ( Figure 3B ; Figure S5A ). In addition to the Ser-644 residue in the C-terminal domain (a.a. 626-673), we identified a new candidate IKKb phosphorylation motif containing Ser-586 and Ser-590 in the adjacent domain (a.a. 579-625) ( Figure S5B ). Using in vitro kinase assays, we showed that these two Ser residues could be phosphorylated by IKKb whereas mutation of these two Ser residues to Ala residues abolished phosphorylation by IKKb ( Figure 3C ), suggesting that Ser-586 and Ser-590 are indeed new IKKb phosphorylation sites. Interestingly, mutations of all these sites (Ser-586, -590, and -644) in the C-terminal domain of FOXO3-(301-673) GST fusion protein abrogated the interaction between bTrCP1 and FOXO3-(301-673)AAA ( Figure 3D ), suggesting that phosphorylation of these sites by IKKb may be crucial for promoting bTrCP1 binding to FOXO3.
It should be noted that bTrCP1 appears to bind to the 301-346 domain of FOXO3 also. It has been well established that bTrCP1 binds to its substrates through the consensus degron domain ''DSGxxS,'' where both serines (S) are phosphorylated by kinases [26] . However, the 301-346 domain of FOXO3 does not contain such a motif, suggesting that this binding may be independent of serine phosphorylation and IKKb-mediated phosphorylation. Although it is interesting that bTrCP1 binds to a site of FOXO3 lacking the degron motif, details of the mechanism underlying the interaction between bTrCP1 and FOXO3 through a phosphorylation-independent manner remain to be elucidated.
Next, we determined the subcellular localizations of bTrCP1 and FOXO3 proteins and whether endogenous FOXO3 was colocalized with bTrCP1 in cancer cells. Using fluorescence microscopy, we showed that bTrCP1 protein is mainly localized in the nucleus of MCF-7 cells without treatment with any proteasome inhibitor by using the specific anti-bTrCP1 polyclonal Ab [22] , kindly provided by Klaus Strebel (at NIH). However, bTrCP1 can be clearly detected in the cytoplasm also ( Figure 3E ). Although endogenous FOXO3 protein was located more in the cytoplasm than nucleus under the same conditions, the majority of FOXO3 was co-localized with bTrCP1 protein in the cytoplasm of MCF-7 cells ( Figure 3E ). In contrast, the treatment with the IKKb inhibitor, bTrCP1 is predominantly detected in the nucleus with this anti-bTrCP1 (NIH) Ab and FOXO3 is also primarily localized in the nucleus ( Figure 3F ). In addition, we have provided data showing similar subcellular localization of endogenous bTrCP1 in BT-549 cells using this specific anti-bTrCP1 Ab ( Figure S6A ).
Since it has been shown that bTrCP1 is mainly localized in the nucleus [22] [23] [24] [25] [26] , we sought to rule out the possibility that the observed partial cytoplasmic localization of bTrCP1 may be due to an antibody artifact. To confirm subcellular localization of overexpressed bTrCP1-myc (myc tagged) in different cell types, we transfected MCF-7 and 293T cells with the bTrCP1-myc expression vector and performed immuno-fluorescence (IF) analysis with an anti-myc tag Ab and this specific anti-bTrCP1 (NIH) Ab. In agreement with the previous results, our new data showed that the IF images of both anti-myc and anti-bTrCP1 (NIH) Abs are colocalized mainly in the nucleus but they can be detected in the cytoplasm, at a relatively lower level, reproducibly ( Figure S6B,C) , suggesting that some bTrCP1 may be truly localized in the cytoplasm under normal conditions. In fact, these results are consistent with the previously published reports [24, 25] .
Recently, multiple isoforms of bTrCP1 and bTrCP2 derived from alternative splicing have been found to display differential activities in the regulation of Wnt signaling in MCF-7 cells [27] , where bTrCP1-mediated degradation of b-catenin mainly occurs in the cytoplasm [25] . Interestingly, some isoforms of bTrCP1 are localized in both cytoplasm and nuclei (i.e., isoforms ''f'' and ''o'' [27] ). As most anti-bTrCP1 polyclonal Abs cannot distinguish those isoforms of bTrCP1, it is plausible that some bTrCP1 proteins detected in the cytoplasm by the specific anti-bTrCP1 Ab may represent certain isoforms such as ''f'' and ''o'' of bTrCP1.
In agreement with previous reports [1] [2] [3] 5, 19] , phosphoryated FOXO3 is mainly localized in the cytoplasm. Using IF analysis, we further confirm that serine (Ser) residues of FOXO3 proteins were phosphoryated in 293T and MCF-7 cells cotransfected with FOXO3-HA (or FOXO3-myc) plus IKKb vectors and primarily localized in the cytoplasm ( Figure S7B,D) , whereas the mutant FOXO3-S644A protein was predominantly localized in the nucleus even in cells overexpressed IKKb ( Figure S8A ). As controls, we showed that mutant FOXO3-S644A protein was also primarily localized in the nucleus in cells without IKKb overexpression ( Figure S8B ). In contrast, we showed that wt FOXO3-HA protein was primarily colocalized with IKKb in the cytoplasm of cells overexpressed IKKb ( Figure S8C ) while wt FOXO3-HA could be detected in the cytoplasm and nucleus without IKKb overexpression ( Figure S8D) .
As cells express a homolog of bTrCP1 (bTrCP2), we examined if bTrCP2 protein could interact with FOXO3 protein in vitro and in vivo. Using GST pull-down assays, we showed that bTrCP2 protein could not bind to FOXO3 protein directly in vitro ( Figure  S9A ). Using IF analysis, we showed that bTrCP2 protein could be detected in both the cytoplasm and nucleus while FOXO3 protein was primarily located in the cytoplasm ( Figure S9B) . Although it appears that bTrCP2 may be localized somewhat more in the nucleus than cytoplasm, it is possible that some isoforms of bTrCP2 [27], as described above, are located more in the nucleus than cytoplasm. Thus, it is probable that FOXO3 protein may not be co-localized with bTrCP2 in cells under normal conditions ( Figure S9B ). Collectively, these data suggest that the Ubmediated FOXO3 protein degradation is mainly mediated through bTrCP1 but may not be regulated by bTrCP2. These results further suggest that cells in which bTrCP1 is silenced alone and bTrCP1(2/2) MEFs express high levels of FOXO3 protein.
Moreover, we determined if this increase of FOXO3 protein by silencing bTrCP1 would affect cell survival or death after DNA damage. We showed that exposure of bTrCP1(-/-) MEF cells to camptothecin (CPT), a topoisomerase I inhibitor, for 48 hours led to cellular apoptosis, whereas wt MEFs did not have significant apoptosis (Figure 4A ,B). As described above, silencing bTrCP1 increased FOXO3 protein significantly ( Figure 2B-D) , suggesting that the observed pro-apoptotic phenotype in cells lacking bTrCP1 may be mediated via FOXO3 increase. To further confirm that the apoptotic effect from silencing bTrCP1 was mediated via FOXO3, we showed that silencing both FOXO3 and bTrCP1 together (double knockdown) in BT549 cells abrogated the effect of apoptosis induced by bTrCP1 single Lysates from 293T cells were incubated with fusion proteins GST-FO (301-673) and GST-FO (301-673)AAA, whose Ser-586, Ser-590, and Ser-644 residues were mutated to Ala residues in the C-terminal domain of FOXO3, and GST protein, and analyzed by IB with an anti-bTrCP1 Ab (upper panel) and an anti-GST Ab (lower panel). The significant signal is indicated with *. (E) MCF-7 cells were treated with DMSO (control vehicle for the IKKb inhibitor shown in F below) or untreated, fixed, and the subcellular localizations and co-localization of endogenous FOXO3 and bTrCP1 proteins were detected using an anti-FOXO3 and a specific anti-bTrCP1 Ab (obtained from K. Strebel at NIH) [22] and followed by an Alexa Fluor 594-or 488-conjugated secondary Ab, respectively, and fluorescence microscopy. DAPI was used to show the nuclei, and colocalization of FOXO3 with bTrCP1 was shown as the merged images (yellow). These results are the same as those untreated cells. (F) MCF-7 cells were treated with the IKKb inhibitor (2 mM), fixed, and the subcellular localizations and co-localization of endogenous FOXO3 and bTrCP1 proteins were detected using Abs against FOXO3 and bTrCP1 (NIH) as described above and followed by an Alexa Fluor 594-or 488-conjugated secondary Ab, respectively, and fluorescence microscopy. DAPI was used to show the nuclei, and no co-localization (the merged yellow images) between nuclear FOXO3 and cytoplasmic bTrCP1 was detected. doi:10.1371/journal.pone.0011171.g003 Figure 4 . DNA damage induces apoptosis in cells lacking bTrCP1 that can be reverted by silencing FOXO3 and ectopic expression of bTrCP1 promotes tumor growth whereas silencing bTrCP1 in cancer cells suppresses tumorigenesis in vivo. (A) DNA samples extracted from Wt MEF or bTrCP1(-/-) MEF cells treated with camptothecin (CPT) (20 mM) for 24 or 48 h or control (DMSO) were subjected to DNA fragmentation assay. Equal amounts of the extracted DNA (2 mg/lane) and size markers (M) were subjected to electrophoresis on 2% agarose gels, which were stained with ethidium bromide and photographed. (B) MEF cells treated with CPT (20 mM) or DMSO (control) (0 h) for 48 h were stained with propidium iodide (PI), and the cell-cycle profiles were determined by flow cytometry. The changes in percentage of cell-cycle statuses between CPT treatment and control were shown in a histogram. (C) BT549 cells were transfected with bTrCP1-siRNA (si-bTrCP1) or control RNA (si-control). DNA fragmentation assay was performed as described above. (D) BT549 cells were transfected with control RNA (si-control) alone or transfected with FOXO3-siRNA (si-FOXO3) plus bTrCP1-siRNA (si-bTrCP1). DNA fragmentation assay was performed. (E) The 231 cells were transfected with bTrCP1-siRNA (designated 231-bTrCP-kd) or transfected with a bTrCP1 expression vector (designated 231-bTrCP-ov). These transfected cells or 231 control cells were injected into the nude mice as described. *, P,0.05 between 231 control versus 231-bTrCP-kd or 231-bTrCP-ov. (F) At 28 days after tumor cell implantation, breast tumors derived from the nude mice bearing 231 (control) or 231-bTrCP-ov or -bTrCP-kd tumors were resected, fixed, sectioned, and placed on slides. Tumor specimens were subjected to immuno-histochemical staining with an Ab specific to bTrCP1 or FOXO3. Slides were examined at 406 magnification with a microscope and representative fields are shown. Scale bars indicate 50 mm. knockdown after exposure to CPT (Figure 4C,D) , suggesting that the effect of silencing bTrCP1 on the observed apoptosis increase is mediated through FOXO3.
We sought to determine whether silencing endogenous bTrCP1 expression could augment FOXO3 protein level and lead to tumor suppression in vivo and whether ectopic expression of bTrCP1 could reduce FOXO3 protein level and promote tumor growth in an orthotopic breast tumor mouse model. When the MDA-MB-231 (abbreviated as 231) cells with bTrCP1-knockdown (231-bTrCP-kd) or 231 control cells were injected into the mammary fat pads of female athymic nude mice, the tumor growth of 231-bTrCP-kd was strongly suppressed as compared to that of 231 control cells ( Figure 4E ). This tumor suppression phenotype is presumably caused by elevation of FOXO3 that promotes apoptosis. In contrast, when the cells over-expressing bTrCP1 (231-bTrCP-ov) were injected into nude mice in the same fashion, the growth rate of 231-bTrCP-ov cells was enhanced as compared to that of 231 control cells ( Figure 4E ). This growth increase is presumably induced by the bTrCP1-mediated FOXO3 degradation as described above. Using immunohistochemical staining and IB analysis, we confirmed that the level of FOXO3 was indeed inversely correlated with the expression level of bTrCP1 in the xenograft tumor samples ( Figure 4F ,G). Because 231 cells are tumorigenic in nude mice and the level of endogenous FOXO3 in 231 cells is low, over-expression of bTrCP1 in 231 cells (231-bTrCP-ov) could only further reduce FOXO3 protein level slightly. Therefore, the tumor growth rate of 231-bTrCP-ov cells in mice could be enhanced only partially as compared to that of 231 control cells ( Figure 4E) .
We have demonstrated a novel mechanism underlying the Ubmediated degradation of FOXO3 protein in tumorigenesis. Our findings indicate that bTrCP1 interacts with FOXO3, resulting in promoting Ub-mediated degradation of FOXO3 protein that contributes to tumor growth. This is the first time that bTrCP1 is shown to regulate FOXO3 protein degradation and its tumor suppressor function. Based on these findings, we propose a model for a unique role of bTrCP1 in regulating FOXO3 protein degradation and promoting tumorigenesis ( Figure 4H ). These findings suggest that cancer cells may acquire sustained resistance to FOXO3-mediated apoptosis through a regulated degradation of FOXO3 protein by bTrCP1 oncogenic E3-ligase. Evidence is emerging to indicate that certain key substrates are targeted by the E3 ligases in the Ub-mediated protein regulation [28] . In addition to FOXO3, it is intriguing that bTrCP1 has been found to interact with another key tumor suppressor p53 [29] and promote its Ubdependent degradation, resulting in tumorigenesis. Our findings that a unique oncogenic bTrCP1 E3-ligase mediates augmented degradation of FOXO3 protein will significantly contribute to an understanding of the control of FOXO3 protein stability and extend the parallel mechanism of regulation between FOXO3 and p53 in cancer cells. Moreover, this dual inhibition of FOXO3 and p53 tumor suppressor function by bTrCP1 suggests that compounds inhibiting bTrCP1 protein may be innovative therapeutic modalities for suppression of tumor growth and the development of cancer.
Materials and Methods

Ethics Statement
All experiments involving mice were approved by the institutional review boards of Stanford University and Albert Einstein College of Medicine. All research involving animals were conducted according to the guidelines of Institutional Animal Care and Use Committees of Stanford University and Albert Einstein College of Medicine. The injected mice were housed in groups, which were provided with food and sterile water. When bedding was contaminated, the mice were transferred into clean cage first and the contaminated bedding was discarded according to Institutional guidelines. There was no change after the appearance of tumors and no nesting material was provided for these mice. The mice were checked daily including weekend. 
Antibodies and reagents
Cell culture and cell lines
All cell lines were grown under normal conditions at 37uC and 5% CO 2 in DMEM/F12 supplemented with L-glutamine, penicilline/streptomycin and 10% fetal bovine serum (FBS). The tumor type origins of the cell lines are: MDA-MB-231 and MCF-7, human breast epithelial adenocarcinoma; BT474 and BT549, human breast epithelial ductal carcinoma; 293T, human kidney epithelial cell line expressing SV40 large T antigen. Mouse embryonic fibroblasts (MEF) bTrCP1(-/-) and their control wt MEF cells have been described previously [30] .
Immunoprecipitation (IP) and immunoblotting (IB)
All IP experiments were performed as described previously [17] . Briefly, cells were washed twice with PBS and lysed with lysis buffer containing protease inhibitors at 4uC for 20 min. Total lysates were sonicated extensively for preventing non-specific protein-protein associations. For Ub analysis, the lysates were prepared with lysis buffer under denaturing conditions and sonicated extensively to prevent non-covalent protein-protein associations. Protein samples were first precleared with a nonspecific IgG antibody. Precleared lysates were then incubated with an Ab by rotating at 4uC overnight followed by the addition of 25 ml of 50% protein A-or Protein G-sepharose slurry and rotating for 1 hour. Protein A/G beads were collected and washed with lysis buffer four times. Immunoprecipitates were resolved by 6% or 10% or 12% SDS-polyacrylamide gel eletrophoresis (PAGE) and analyzed by IB analysis. After washing, immunoprecipitates were resolved by SDS-PAGE and analyzed by IB analysis. For IB analysis, the protein samples were subjected to SDS-PAGE and transferred onto nitrocellulose or polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% nonfat dry milk or BSA in PBS containing 0.05% Tween 20 and incubated with primary Abs and then with horseradish peroxidase-conjugated secondary Abs according to the manufacturer's instructions. IB analysis was visualized by an enhanced chemiluminescence (ECL) kit obtained from Pharmacia or Santa Cruz Biotechnology.
In vitro ubiquitination assays E3-ligase proteins (GST-bTrCP1 and GST-bTrCP1DF) and target proteins (GST (negative control), GST-FO(1-300), and GST-FO(301-673)) were produced as GST-fusion proteins from E. coli and purified. In vitro ubiquitination assays were carried out using in vitro ubiquitination assay kit (BIOMOL). In vitro ubiquitination assays were carried out in 50 ml of ubiquitinylation buffer, containing E1 (100 nM), E2 (UbcH5b, 2.5 mM), Mg-ATP (5 mM), E3 (0.1 mM), target protein (1 mM), inorganic pyrophosphatase solution (100 U/ml), DTT (5 mM), Mg-ATP (25 nM), biotinylated ubiquitin (2.5 mM), and the cell extracts (5 mg protein) from 293T cells over-expression of IKKb. The reaction mixtures were incubated for 2 hours at 37uC and then terminated with 2X nonreducing gel loading buffer. The protein samples were subjected to SDS-PAGE (8% gel) and transferred onto nitrocellulose membrane. The membranes were incubated with streptavidin-HRP solution (Vectastain ABC Elite kit) for 1 hour, washed with BSA/TBST (Tris-buffered saline containing 0.05% Tween 20) solution for 1 hour and visualized by chemiluminescence.
Immunofluorescence (IF)
MEF bTrCP1(-/-) and bTrCP1(+/+) cells were seeded onto sterile glass coverslips, which were placed in a 12-well culture plate. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature before being permeabilized in 0.5% Triton X-100. Slide culture chambers were washed with PBS and blocked with PBS containing 2% BSA, incubated with an Ab specific to FOXO3 or bTrCP1 (1:100 to 1:500 dilution), followed by Alexa 546 or 555 or 594 or 647 (red)-conjugated anti-rabbit and Alexa 488 (green)-conjugated anti-mouse secondary Abs (Molecular Probes, Eugene, OR). Cells were counterstained with DAPI (Molecular Probes, Eugene, OR) to show the nuclei. Specific staining was visualized and images were captured with a Leica SP2 AOBS confocal laser scanning microscope or an Olympus IX81 system confocal microscope as described previously [17] .
siRNA transfection MCF-7 or 293T cells were transfected with specific smallinterfering RNA (siRNA) targeting FOXO3 (si-FOXO3a) (59-GAGCUCUUGGUGGAUCAUC d T d T-39) or bTrCP1 (bTrCP1 siRNA duplexes were obtained from Dharmacon) or control luc siRNA (59-CUUACGCUGAGUACUUCGA d T d T-39) duplex (Dharmacon) (4 uM/2610 6 cells) by electroporation using Nucleofector 1 (amaxa) or Lipofectamine 2000 (Invitrogen Corp.) as described previously [17] . The control vector (without shRNA), the scrambled shRNA control vector, and the bTrCP1-shRNAs vectors were purchased from OriGene Technologies, Inc. (Rockville, MD).
DNA fragmentation Assay
DNA fragmentation in apoptotic cells was determined by the standard gel electrophoresis. Cells were treated with the indicated drugs or control for 24 or 48 hours, harvested, washed with PBS, and incubated with lysis buffer on ice for 20 min. Samples were then centrifuged at 4uC at 12,0006g for 30 min. DNA was extracted with phenol/chloroform and precipitated with ethanol.
The DNA pellet was then washed with 70% ethanol, dissolved in water containing RNase, and incubated at 37uC for 30 minutes. The extracted DNA (2 mg/lane) was subjected to electrophoresis on 2% agarose gels, stained with ethidium bromide, and then photographed.
Cell cycle analysis
Wild type (Wt) and bTrCP1(-/-) MEF cells were treated with CPT (20 mM) or control (DMSO) for 5 hours. Cells were rinsed with PBS and fixed in 70% ethanol at 4uC overnight. The fixed cells were then washed twice with PBS and resuspended in PBS containing 10 mg/ml PI (Roche Applied Science) and 10 mg/ml RNase A (Sigma), and incubated for 1 hour at room temperature before analysis. The samples were analyzed by flow cytometry as described previously [17] . Cell populations in different phases of cell cycle were determined.
GST pull-down assays
For GST pull-down assays: the various GST-fusion FOXO3 plasmids containing the specific domains of FOXO3 (GST-FO-(1-301), (301-673), (301-346), (347-392), (393-439), (440-485), (486-531), (532-578), (579-625), and (626-673)) were prepared. The various GST-fusion FOXO3 expression vectors were constructed as described previously [17] . Briefly, the GST-FO fusion proteins and GST proteins (control) were expressed in Escherichia coli BL21 (Invitrogen, Carlsbad, CA) lysed in a GST lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, and protease inhibitors), and immobilized onto glutathioneSepharose beads (Pharmacia Biotech). Total lysate (1 mg) from 293T cells that were transfected with IKKb or treated with TNFa (10 ng/ml) in binding buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 0.5% Nonidet P-40 and protease inhibitors) was mixed with the GST-FO or GST (control) containing glutathione-Sepharose beads. The protein complex formation on glutathione-Sepharose beads was carried out overnight at room temperature or 4uC with shaking. The beads were washed with binding buffer, and the bound protein complexes were disrupted and proteins were denatured directly by boiling in SDS loading buffer.
Immunohistochemical staining and statistical analysis
Immunohistochemical staining was performed as described previously [17] . Breast tumors were excised from the tumorbearing mice 28 days (231-control, 231-bTrCP-ov, and 231-bTrCP-kd tumors) after inoculation of the test or control cells. Five independent tumors (each from a different mouse) were taken from each test group for testing. Tumor samples were fixed in formalin, sectioned, placed on slides, and incubated with specific Abs. Sections were then treated with biotin-conjugated secondary Ab followed by avidin biotin-peroxidase complex and amino-ethyl carbazole as a chromogen. All data are expressed as means and standard deviations (SD) from at least three determinations. The statistical significance of differences in cell proliferation and tumor growth between two groups was analyzed with two-sided unpaired Student's t tests when the variances were equal, or with Welch's corrected t tests when the variances were unequal, with Graphpad statistical software (San Diego, CA). All statistical tests were twosided, and P values less than 0.05 were considered statistically significant.
Animal studies
To determine tumorigenicity and establish orthotopic breast cancer animal models, female athymic (nu/nu) nude mice were BT-549 breast cancer cells were treated with DMSO, fixed, and the subcellular localizations and colocalization of endogenous FOXO3 and bTrCP1 proteins were detected using antibodies (Abs) against FOXO3 and bTrCP1 and followed by an Alexa Fluor 555-or 488-conjugated secondary Abs, respectively, and fluorescence microscopy. DAPI was used to show the nuclei, and co-localizations of FOXO3 with bTrCP1 images are shown as the merged yellow/orange images. (B, C) Overexpression of bTrCP1-myc in MCF-7 cells (B) and 293T cells (C) confirms the subcellular localizations of bTrCP1-myc. At 48 hours after transfection, cells were fixed and stained with Abs against myc-tag or bTrCP1, a specific Ab that was developed by K. Strebel at NIH as described previously [22] , and followed by an Alexa Fluor 647-or 488-conjugated secondary Abs, respectively, and fluorescence microscopy as described above. 
